Finchley Healthcare Ventures
Pierre Beauparlant is an accomplished leader in the biomedical and life sciences sectors, currently serving as Executive Managing Director at Finchley Healthcare Ventures and Executive-in-Residence at UCSF Innovation Ventures since 2023. Previous roles include Venture Partner at Sanderling Ventures and SynLead Therapeutics Inc., and leadership positions such as President & CEO at Ovata Inc., PreciThera, Inc., and SpecificiT Pharma Inc. Pierre's career spans over two decades, with significant contributions to Novartis as Medical Therapeutic Head in Hematology and vice president of research at Gemin X Pharmaceuticals. Pierre holds a Ph.D. in Microbiology & Immunology from McGill University and an MSc in Microbiology from Université de Montréal.
This person is not in any teams
This person is not in any offices
Finchley Healthcare Ventures
Finchley Healthcare Ventures (FHCV) is a Canadian venture capital fund founded in 2022 specializing in investments within the rapidly evolving landscape of life sciences. With a passion for advancing healthcare and a keen focus on fostering innovation, FHCV is dedicated to supporting companies developing new and transformative medicines, as well as investing in other venture capital funds operating in the life sciences sector. FHCV invests in companies that are pushing the boundaries of medical research and development, with a particular emphasis on those developing novel therapies. FHCV seeks out opportunities where breakthrough technologies and transformative ideas have the potential to address significant unmet medical needs and revolutionize patient care. The organization also invests in venture capital funds specializing in life sciences and seeks to leverage their expertise and network to access a diverse range of investment opportunities. This approach allows FHCV to diversify its portfolio while also benefiting from the specialized knowledge and due diligence capabilities of these investment partners.